Hasil Pencarian  ::  Simpan CSV :: Kembali

"Pasien dengan kanker payudara banyak yang mengalami gangguan dan hampir seluruhnya mengalami depresi yang dapat memperberat gejala fisik, meningkatkan gangguan fungsional, dan membuat kepatuhan berobat menjadi rendah. Kami melakukan tinjauan pustaka yang tersedia di PubMed tentang prevalensi, besar gangguan, kemampuan coping, dan metode penatalaksanaan depresi berat pada wanita dengan kanker payudara dari tahun 1978 sampai 2010. Diagnosis dan penatalaksanaan episode depresi pada wanita dengan kanker payudara merupakan tantangan karena gejala yang tumpang tindih dan kondisi penyerta. Depresi berat sering disepelekan dan penatalaksanaan tidak adekuat pada pasien kanker payudara. Tinjauan ini menekankan pada masalah dalam identifikasi dan pengelolaan depresi pada pasien kanker payudara dengan latar klinis.

---

AbstractMany of breast-cancer patients experience distress and most of them experience depression which may lead to amplification of physical symptoms, increased functional impairment, and poor treatment adherence. We did a review on available literature from PubMed about prevalence, distress magnitudes, coping styles, and treatment methods of major depression in women with breast cancer from 1978 to 2010. Diagnosis and treatment of depressive episodes in women with breast cancer is challenging because of overlapping symptoms and co-morbid conditions. Major depression is often under-recognized and undertreated among breast cancer patients. This review highlighted the issues on identifying and managing depression in breast cancer patients in clinical settings."

"This important book provides up-to-date information on a series of topical issues relating to the approach to minimal residual disease in breast cancer patients. It first explains how the study of minimal residual disease and circulating and disseminated tumor cells (CTCs/DTCs) can assist in the understanding of breast cancer metastasis. A series of chapters then discuss the various technologies available for the detection and characterization of CTCs and DTCs, pinpointing their merits and limitations. Detailed consideration is given to the relevance of CTCs and DTCs, and their detection, to clinical research and practice. The role of other blood-based biomarkers is also addressed, and the closing chapters debate the challenges facing drug and biomarker co-development and the use of CTCs for companion diagnostic development. This book will be of interest and assistance to all who are engaged in the modern management of breast cancer."

"ABSTRAK Latar Belakang: EORTC menekankan pentingnya menilai kualitas hidup pasien kanker. Saat ini, di Indonesia, belum ada kuesioner yang reliabel dan valid untuk menilai kualitas hidup pasien kanker payudara secara akurat. Tujuan: membuktikan bahwa EORTC-QLQ-BR23 merupakan kuesioner yang reliabel dan valid digunakan di Indonesia Metode: Penelitian dimulai dengan menerjemahkan EORTC-QLQ-BR23 ke dalam bahasa Indonesia dan kemudian diujicobakan pada 10 responden. Setelah itu, EORTC QLQ-BR23 hasil terjemahan digunakan pada penelitian utama. Test-retest dinilai dengan Intraclass Correlation Coeficient (ICC). Konsistensi internal dinilai dengan cronbach alpha. Construct validity dinilai dengan multi-trait scaling analysis. Validitas kriteria dinilai dengan melihat korelasi antara domain EORTC-QLQ-C30 dan EORTC-QLQ-BR23 dengan SF36. Hasil: Telah dilakukan pengambilan data terhadap 100 pasien kanker payudara dari September ? Oktober 2015. Nilai ICC (interval 1 jam) pada semua domain sangat baik (ICC > 0,8). Nilai cronbach alpha > 0,7 pada hampir semua domain. Multi-trait scaling analysis menunjukkan korelasi cukup tinggi antara skor pertanyaan dengan skor domainnya sendiri. Uji validitas kriteria, didapatkan 19 korelasi dengan r > 0,3 antara domain EORTC-QLQ-C30 dan EORTC-QLQ-BR23 dengan SF36. Simpulan: EORTC-QLQ-BR23 merupakan kuesioner yang reliabel dan valid digunakan di Indonesia.ABSTRACT Background: EORTC emphasize the importance of assessing quality of life in cancer patients. In Indonesia, there has been no reliable and valid questionnaire to assess quality of life of breast cancer patients accurately. Objective: To prove that EORTC-QLQ-BR23 is reliable and valid questionnaire used in Indonesia. Methods: Study began with the EORTC-QLQ-BR23 translated into Indonesian and then tested on 10 respondents. Indonesian version of EORTC-QLQ-BR23 is used in main study. Test-retest was assessed with intraclass correlation coeficient (ICC). Internal consistency was assessed by Cronbach alpha. Construct validity was assessed by multi-trait scaling analysis. Criteria validity assessed by looking at correlation between EORTC-QLQ-C30 and EORTC-QLQ-BR23 with SF36. Results: Data collection were done on 100 breast cancer patients from September to October 2015. ICC value (1 hour interval) in all domains of EORTC-QLQ-BR23 is very good (ICC> 0.8). Cronbach alpha values >0.7 in almost all EORTC-QLQ-BR23 domains. Multi-trait scaling analysis showed a high correlation between scores of questions with a score of his own domain. Criteria validity test, obtained 19 correlation with r>0,3 between domains EORTC-QLQ-C30 and EORTC-QLQ-BR23 with SF36. Conclusion: EORTC-QLQ-BR23 is a reliable and valid questionnaire used in Indonesia.;Background: EORTC emphasize the importance of assessing quality of life in cancer patients. In Indonesia, there has been no reliable and valid questionnaire to assess quality of life of breast cancer patients accurately. Objective: To prove that EORTC-QLQ-BR23 is reliable and valid questionnaire used in Indonesia. Methods: Study began with the EORTC-QLQ-BR23 translated into Indonesian and then tested on 10 respondents. Indonesian version of EORTC-QLQ-BR23 is used in main study. Test-retest was assessed with intraclass correlation coeficient (ICC). Internal consistency was assessed by Cronbach alpha. Construct validity was assessed by multi-trait scaling analysis. Criteria validity assessed by looking at correlation between EORTC-QLQ-C30 and EORTC-QLQ-BR23 with SF36. Results: Data collection were done on 100 breast cancer patients from September to October 2015. ICC value (1 hour interval) in all domains of EORTC-QLQ-BR23 is very good (ICC> 0.8). Cronbach alpha values >0.7 in almost all EORTC-QLQ-BR23 domains. Multi-trait scaling analysis showed a high correlation between scores of questions with a score of his own domain. Criteria validity test, obtained 19 correlation with r>0,3 between domains EORTC-QLQ-C30 and EORTC-QLQ-BR23 with SF36. Conclusion: EORTC-QLQ-BR23 is a reliable and valid questionnaire used in Indonesia."

"Penatalaksanaan kanker payudara mungkin merupakan suatu hal yang amat kontroversial dan telah mengalami perubahan luarbiasa dengan berjalannya waktu. MRI dengan kontras muncul sebagai alat diagnostik pencitraan yang paling efisien. Pendekatan yang mutakhir untuk biopsi kanker payudara yang tidak sesuai untuk pembedahan, ditujukan untuk mendapatkan sampel jaringan yang cukup untuk keperluan diagnostik namun meminimalkan penyebaran dan resiko komplikasi. Penanganan regional yang dilakukan Halstead secara ketat, walaupun berhasil mengendali lokal regional secara bermakna, namun tidak berhasil meningkatkan kesintasan (survival) jangka panjang. Dengan berjalannya waktu, orang telah memahami disposisi sistemik penyakit ini dan pentingnya menggabungkan terapi sistemik bahkan sejak tahap dini dan melengkapi teknik ablatif surgikal. Peranan terapi sistemik primer dalam manajemen kanker payudara dengan cepat muncul sebagai suatu pilihan yang vital. Pada pasien dengan ekspresi berlebih gen HER 2/neu, tambahan ?transtuzumab? pada pengobatan sistemik menghasilkan peningkatan yang jelas pada kesintasan secara keseluruhan.

---

AbstractThe management of breast cancer is perhaps the most controversial of all and has evolved a sea change over the years. Contrast enhanced MRI imaging is emerging as the most efficient imaging diagnostic tool. Newer approaches for the biopsy of inoperable breast cancer are aimed at obtaining diagnostically adequate tissue samples while minimizing invasiveness and the risk of complications. The regional vigour that Halsted followed rigorously, albeit, achieved significant locoregional control, could not lead to improved long-term survival. With the passage of time, people have understood the systemic nature of the disease and the paramount need to incorporate systemic treatment even in relatively earlier stages and curtain surgical ablative techniques. The role of primary systemic therapy in the management of breast cancer is fast emerging as a vital option. In HER 2/neu gene overexpressed patients, addition of trastuzumab to the systemic treatment is a distinct improvement in overall survival. "

"Doxorubicin dan docetaxel masing-masing dikenal sebagai obat sitotoksik yang aktif untuk pengobatan kanker payudara metastatik (KPM). Kombinasi keduanya juga telah memperlihatkan derajat aktivitas yang tinggi sebagai kemoterapi lini kedua untuk KPM. Penelitian ini bertujuan untuk mengevaluasi keampuhan dan keamanan kombinasi docetaxel-doxorubisin sebagai kemoterapi lini pertama untuk penderita KPM di Indonesia. Sebanyak 26 pasien wanita berusia 31-65 tahun dengan KPM diikutsertakan dalam studi. Pasien belum pernah mendapat taxane atau doxorubicin kumulatif sebesar 250 mg/m2 serta tidak menderita penyakit jantung. Terapi terdiri dari doxoubicin 50 mg/m2 sebagai bolus intravena (IV) diikuti satu jam kemudian oleh docetaxel 60 mg/m2 dengan infus IV selama 1 jam, setiap 3 minggu untuk 6 siklus. Premedikasi dengan kortikosteroid oral diberikan sehari sebelum kemoterapi sampai hari kedua setiap siklus. Fraksi ejeksi ventrikel kiri direkam di awal studi dan setelah siklus ke-6. Di akhir studi, secara total telah diberikan 156 siklus kemoterapi. Lima dan 11 orang pasien mengalami respons komplit (RK) dan parsial (RP), berturut-turut, yang menjadikan respons keseluruhan terbaik sebesar 61,54%. Tiga orang pasien dengan metastatis hepar luas tampak hilang sama sekali setelah 6 siklus. Toksisitas derajat 3-4 tersering adalah leukopenia (80,77%) dan febrile neutropenia (5,77%). Leukopenia biasanya singkat, dan terutama terjadi pada siklus pertama dan kedua serta tidak membutuhkan penurunan dosis. Tidak ada pasien yang mengalami gagal jantung. Terdapat satu kematian akibat penyakit yang progresif setelah 6 siklus. Kombinasi doxorubicin 50 mg/m2 dan docetaxel 60 mg/m2 tampak aktif sebagai kemoterapi lini pertama pada KPM, khususnya pada pasien dengan metastatis hepar, dengan profil toksisitas yang dapat ditatalaksana. (Med J Indones 2004; 14: 20-5)

---

Doxorubicin and docetaxel as a single agent are known as active cytotoxic agents for the treatment of metastatic breast cancer (MBC). Their combination has also shown to be highly active as a second-line chemotherapy of MBC. This study was design to evaluate the efficacy and safety of docetaxel-doxorubicin combination as first line chemotherapy of MBC patients in Indonesia. Twenty-six female patients between 31-65 years old with advanced or MBC was enrolled. No prior taxane or cumulative doxorubicin of 250 mg/m2 was allowed and patients should not have a heart disease. Treatment consisted of doxorubicin 50 mg/m2 as intravenous (IV) bolus followed one hour later by docetaxel 60 mg/m2 by IV infusion over 1 hour every 3 weeks for 6 cycles. Premedication with oral corticosteroid was administered a day prior to chemotherapy until the second day of each cycle. Left ventricular ejection fraction was recorded at baseline and after the 6th cycle. At the end of study, a total of 156 cycles of chemotherapy have been delivered. Five and 11 patients had a complete response (CR) and partial response (PR), respectively, which accounted for a 61.54% best overall response. Three patients with extensive liver metastases showed complete disappearance after 6 cycles. Most frequent grade 3-4 toxicities were leukopenia (80.77%) and febrile neutropenia (5.77%). Leukopenia was usually short in duration, occurred mainly during the first and second cycle and did not require dose reduction. No patient developed heart failure. There was one death due to progressive disease after 6 cycles. Combination of doxorubicin 50 mg/m2 and docetaxel 60 mg/m2 was sufficiently active as first-line chemotherapy of MBC, especially in patients with liver metastases, with a manageable toxicity profile. (Med J Indones 2004; 14: 20-5)"

"Tujuan: untuk menganalisis penanda biologi CXCR4, IL11-RA, TFF1 dan MLF1P, klinikopatologi dan profil ekspresi genetik mRNA sebagai penanda peningkatan kejadian metastasis tulang pada pasien kanker payudara stadium lanjut.Metode: studi ini merupakan penelitian potong lintang. Analisis dilakukan pada total 92 pasien kanker payudara, terdiri atas 46 pasien metastasis tulang dan 46 pasien dengan metastasis nontulang. Analisis imunohistokimia dan microarray, dilakukan pada 81 sampel formalin fixed paraffin embedded (FFPE) dari 81 pasien yang didapat. Data dikumpulkan melalui rekam medis, pemeriksaan imunohistokimia (IHK), dan microarray dengan nanoString nCounterTM.Hasil: artikel ini merupakan bagian satu dari dua tahap pelaporan hasil penelitian. Pada tahap satu diperoleh hasil analisis IHK, IL11-RA dengan cut-off ≥103,5 menunjukkan peningkatan kejadian metastasis tulang, dengan OR 3,803 (95 % interval kepercayaan [IK], 1,375-10,581), p=0,010, dan MLF1P dengan cut-off ≥83,0 menunjukkan peningkatan kejadian metastasis tulang, dengan OR 2,784 (95% IK, 1,009-7,681), p=0,048. Status ER+ menunjukkan peningkatan kejadian metastasis tulang, dengan OR 7,640 (95 % IK, 2,599-22,459), p<0,000. AUC gabungan IL-11RA, MLF1P dan ER+, mempunyai ketepatan hampir 80% (meningkat dibandingkan AUC masing-masing secara terpisah), untuk membedakan dan menjelaskan kejadian metastasis tulang, pada kanker payudara stadium lanjut.Kesimpulan: IL11-RA, MLF1P dan ER+, merupakan determinan peningkatan kejadian metastasis tulang pasien kanker payudara stadium lanjut.

---

Aim: to analyze expression of biomarkers CXCR4, IL11-RA, TFF1 and MLF1P, and clinico pathology in advanced breast cancer patients with bone metastatic.Methods: this is a cross-sectional study. Analysis was done against a total of 92 breast cancer patients, including 46 bone metastatic patients and 46 non-bone metastatic patients. Immunohistochemistry and microarray analysis was performed in 81 formalin fixed paraffin embedded (FFPE) samples from 81 patients were used. Data were collected through medical records, immunohistochemistry (IHC), and microarray with nanoString nCounterTM. Results: this article is part one of a two stage reporting research results. In part one we got the results of the IHC analysis, IL11-RA with cut-off ≥103.5 showed OR 3.803 (95 % confidence interval [CI], 1.375-10.581), p=0.010, MLF1P with cut-off ≥83.0 OR 2.784 (95% CI, 1.009-7.681), p=0.048, and ER+ OR 7.640 (95 % CI, 2.599-22.459), p<0.000, were associated with bone metastastic incidences in advanced breast cancer, and were statistically significantly different. A combination of IL-11RA, MLF1P and ER+, showed an accuracy of approaching 80% to discriminate between bone metastatic and non bone metastatic in advanced breast cancer patients.Conclusion: IL11-RA, MLF1P, and ER+ were the determinants that were associated with increasing bone metastasis incidence."

"ABSTRAKKeterlambatan pengobatan kanker payudara merupakan masalah serius yang dapat memengaruhi kesintasan hidup seseorang. Terutama mereka yang berobat di rumah sakit rujukan, kemungkinan besar telah mengalami keterlambatan berulang. Sehinggu tujuan dalam penelitian ini untuk mengetahui faktor-faktor yang memengaruhi keterlambatan pengobatan kanker payudara tersebut. Penelitian ini merupakan penelitian dengan menggunakan desain cross sectional dengan sampel dari rumah sakit rujukan nasional pada tahun 2013 - 2016. Pengobatan dikatakan terlambat jika membutuhkan waktu lebih dari tiga bulan untuk mendapatkan pengobatan sejak pertama kali datang ke rumah sakit. Penelitian ini menggunakan analsisi cox regresi dengan tingkat kemaknaan 0,005. Hasil penelitian ini didapatkan bahwa faktor yang paling memengaruhi keterlambatan pengobatan pada pasien yang pernah mendapatkan pengobatan adalah tempat tinggal PR 1,593 95 CI 1,031 ndash; 2,462 . Kemudian faktor yang memengaruhi keterlambatan pada pasien baru adalah tingkat pendidikan PR 1,743 95 CI 1,025 ndash; 2,997 dan riwayat pengobatan alternative PR 2,741 95 CI 1,419 ndash; 5,296.

---

ABSTRACTDelayed treatment of breast cancer is a serious problem that can worsen the survival period. Then, there is patients already experiencing repeated delays. The purpose of this study is to find out what factors influences the delay of treatment. The study was done with cross sectional design taken from 564 samples of patient breast cancer in Cipto Mangunkusumo General Hospital between 2013 and 2016. Data collected based on register hospital. Time of delay treatment that measured the time from the first came to hospital to the first treatment in hospital. Delay was defined when there was more than 3 months from come to hospital to first treatment. The study based on cox regression was used with p value "

"AbstrakBased on data from the Hospital Information System (HIS) in 2007, breast cancer is the top ranked diagnosed cancer in Indonesia. Estrogen receptor alpha (ERα) is associated with breast cancer because it is found in high levels in cancer tissues. Curcumol, curcumenol, isocurcumenol of white tumeric rhizomes (Curcuma zedoaria (Christm.) Roscoe), and β-sitosterol from seeds of pumpkin (Cucurbita pepo L.) have been reported to have inhibitory activity against cancer cells. This study presents the in silico study of these compounds as inhibitors of ERα.Methods: Docking simulations are carried out in this paper to visualize molecular-level interactions between the four compounds with ERα. Docking simulations between estradiol and tamoxifen on ERα are carried out as well.Results: Docking results indicated that curcumol, curcumenol, isocurcumenol, and β-sitosterol showed inhibitory activity againts estrogen receptor alpha (ERα). The order of potency is shown consecutively by isocurcumenol, curcumol, curcumenol, and β-sitosterol with values 0.584 M, 1.36 M, 1.61 M, and 7.35 M respectively. Curcumenol and estradiol interacts with ERα through hydrogen bonds and hydrophobic interactions, whereas curcumol, isocurcumenol, β-sitosterol and tamoxifen through hydrophobic interactions in succession.Conclusion: Natural products containing all four compounds have the potential to be used as drugs or adjuvant drugs in breast cancer therapy."

"Isolasi dan ekspansi sel punca kanker payudara secara in vitro tanpa menghilangkan sifat pluripotensi sel sangat diperlukan untuk mempelajari karakteristik sel punca kanker payudara. Penelitian ini bertujuan untuk mencari suatu kondisi kultur terbaik dengan sistem ko-kultur untuk mempertahankan sifat pluripotensi. Sel tersebut diko-kultur dengan feeder layer yang terbentuk dari Mouse Embryonic Fibroblast (MEF). Pengukuran ekspresi penanda permukaan CD44+/CD24-menggunakan metode spektrofluorometri, sedangkan pengukuran ekspresi gen SOX2 dilakukan secara kuantitatif dengan metode real time polymerase chain reaction. Pada pengukuran ekspresi gen SOX2 dilakukan normalisasi menggunakan house keeping gene PUM1 sebagai kontrol dalam. Hasil penelitian menunjukkan bahwa ekspresi CD44+/CD24-pada sel punca kanker payudara yang diko-kultur dengan MEFs menggunakan media CM dan DMEM lebih tinggi dibandingkan dengan yang tidak diko-kultur dengan MEF menggunakan CM dan DMEM. Ekspresi gen SOX2 meningkat pada sel yang diko-kultur dengan MEF di CM dan sel yang diko-kultur dengan MEF dalam DMEM yaitu berturut-turut 83,28 dan 48,33 kali dari kontrol masing masing. Hasil penelitian menunjukan bahwa kondisi kultur terbaik untuk mempertahankan pluripotensi sel punca kanker payudara adalah ko-kultur dengan MEF menggunakan CM sebagai media.

---

In objective to understand the role and importance of breast cancer stem cells and the molecular and cellular events that occur during cancer development, it is essential to isolate and propagate breast cancer stem cells in long-term in vitro culture without loosing their pluripotency. This study aimed to find the best culture condition with co-cultured system to maintain the breast cancer stem cells pluripotency. The cell cultured on top of a feeder layer formed by mouse embryonic fibroblast (MEF). We observed the expression of breast stem cell markers CD44+/CD24-using spectrofluorometry and analyzed the expression of gene SOX2 using quantitative real-time polymerase chain reaction (qRT-PCR).

Fluorescence spectroscopy results showed that CD44+/CD24-expression of cancer stem cells co-cultured in CM and DMEM high glucose with MEF is higher than one cultured in CM or in DMEM high glucose without MEF only. After being normalized by using house keeping gene, PUM1, SOX2 gene expression levels in cells cultured in CM and DMEM with MEF i.e 83,28 and 48,33 times higher, respectively, compared to their control. Result showed that the best condition to maintain pluripotency of breast cancer stem cells was to co-culture the cells with MEF using CM as medium."